الصفحة الرئيسية>>Natural Products>>Ganoderic acid C2

Ganoderic acid C2

رقم الكتالوجGC36117

حمض الجانوديريك C2 هو ترايتيربينويد النشط بيولوجيًا في غانوديرما لوسيدوميمتلك حمض الجانوديريك C2 النشاط الحيوي المضاد للأورام ، ومضادات الهيستامين ، والتأثيرات السامة للخلايا والشيخوخةيُظهر حمض الجانوديريك C2 نشاطًا مثبطًا عاليًا ضد اختزال ألدوز عدسات الجرذ (RLAR) مع IC 50 من 3.8 ميكرومتر

Products are for research use only. Not for human use. We do not sell to patients.

Ganoderic acid C2 التركيب الكيميائي

Cas No.: 103773-62-2

الحجم السعر المخزون الكميّة
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM[1][2]. IC50: 3.8 µM (RLAR)[2]

[1]. Guo XY, et al. l characterization of minor metabolites and pharmacokinetics of ganoderic acid C2 in rat plasma by HPLC coupled with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2013 Mar 5;75:64-73. [2]. Fatmawati S, et al. Inhibition of aldose reductase in vitro by constituents of Ganoderma lucidum. Planta Med. 2010 Oct;76(15):1691-3.

مراجعات

Review for Ganoderic acid C2

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ganoderic acid C2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.